Milestone Pharmaceuticals to present data at American Heart Association Scientific Sessions 2025.

Milestone Pharmaceuticals will present data on the efficacy, safety, and tolerability of etripamil for paroxysmal supraventricular tachycardia at the American Heart Association Scientific Sessions 2025. The presentation, led by James Ip, M.D., will highlight the results of multiple clinical trials on the self-administered etripamil treatment. The conference will take place in New Orleans, Louisiana, from November 7-10.

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on developing innovative cardiovascular medicines, will present data on the efficacy, safety, and tolerability of etripamil for paroxysmal supraventricular tachycardia (PSVT) at the American Heart Association (AHA) Scientific Sessions 2025. The presentation, led by James Ip, M.D., will highlight the results of multiple clinical trials on the self-administered etripamil treatment. The conference will take place in New Orleans, Louisiana, from November 7 to 10, 2025.

The presentation will offer insights into the potential of etripamil as a treatment for PSVT, a condition characterized by abnormal heart rhythms that can cause symptoms such as palpitations and dizziness. The data will be crucial for evaluating the effectiveness and safety of etripamil as a self-administered therapy, which could provide a significant advancement in the management of PSVT.

Milestone Pharmaceuticals recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil, indicating the company's confidence in the drug's potential to address a critical unmet need in cardiovascular care. The upcoming presentation at the AHA Scientific Sessions is an important milestone in the drug's development and commercialization journey.

Investors and financial professionals will be closely watching the presentation for any new insights that could impact Milestone Pharmaceuticals' stock price and future prospects. The company's ability to demonstrate the efficacy and safety of etripamil in clinical trials will be a key factor in determining its success in the competitive cardiovascular medicines market.